Digital Therapeutics Field Is Fast On The Rise, Ehave Is Advancing Research In Psychedelics And ADHD Therapy

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Ehave, Inc. EHVVF is a provider of digital therapeutics, delivering evidence-based therapeutic interventions to patients. 

Ehave’s main focus is on helping improve the standard care in therapeutics to prevent/treat brain disorders or diseases through the use of digital therapeutics, psychedelics, and other therapies. An initial focus for Ehave has been on the remediation and assessment of attention deficit hyperactivity disorder (ADHD). 

The company’s main product, the Ehave Dashboard, empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.  

CEO of Ehave, Benjamin Kaplan, will be presenting at Benzinga’s upcoming Deal Room. Kaplan will be discussing an opportunity with the company’s ADHD applications and its approach to the psychedelic sector.

He will also be providing an overview of Ehave’s plan to monetize and expand to achieve leadership status in the market.

“I feel very excited about the path Ehave is taking,” said Kaplan. “From the advancing of ADHD research and approvals in this sector to our opportunities arising from the Psychedelic explosion.” 

To learn more about Ehave and its opportunities, you can sign up for Benzinga’s Deal Room by clicking here.

Photo by Toa Heftiba on Unsplash

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.